| Cas No.: | 1137916-97-2 |
| Chemical Name: | 3-(6-ethanesulfonylpyridin-3-yloxy)-5-((1S)-2-hydroxy-1-methyl-ethoxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide |
| Synonyms: | MK-0941,MK0941 |
| SMILES: | C(NC1C=CN(C)N=1)(=O)C1=CC(O[C@H](C)COS(C)(=O)=O)=CC(OC2=CC=C(S(CC)(=O)=O)N=C2)=C1 |
| Formula: | C21H24N4O6S |
| M.Wt: | 460.5 |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Publication: | [1]. Eiki J, et al. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol. 2011 Dec;80(6):1156-65. |
| Description: | MK-0941 is a potent, orally active and allosteric glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 has potential in the treatment of type 2 diabetes[1]. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|
| 2018-0101 |
|